ProShare Advisors
ATYR icon

ProShare Advisors’s aTyr Pharma ATYR Stock Holding History

ProShare Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,905
Closed -$10.8K – 2039
2026
Q1 		$10.8K Sell
13,905
-3,619
-21% -$3.06K ﹤0.01% 1854
2025
Q4 		$13.7K Buy
17,524
+2,651
+18% +$2.18K ﹤0.01% 2029
2025
Q3 		$10.7K Sell
14,873
-2,964
-17% -$13.4K ﹤0.01% 2004
2025
Q2 		$90.4K Buy
+17,837
New +$70.2K ﹤0.01% 1895
2016
Q4 		– Sell
-1,068
Closed -$48K – 1754
2016
Q3 		$48K Sell
1,068
-191
-15% -$8.25K ﹤0.01% 1441
2016
Q2 		$49K Sell
1,259
-35
-3% -$1.63K ﹤0.01% 1553
2016
Q1 		$71K Sell
1,294
-127
-9% -$9.65K ﹤0.01% 1540
2015
Q4 		$196K Buy
+1,421
New +$202K ﹤0.01% 1550

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ProShare Advisors's ATYR Position: Q2 2026 in Review

ProShare Advisors sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 13,905 shares — an estimated $10.8K sold.

ProShare Advisors first reported a position in ATYR in Q4 2015 and held it in 8 quarters. The position peaked at $196K in Q4 2015. 89 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • ProShare Advisors reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • ProShare Advisors sold 13,905 aTyr Pharma shares in Q2 2026, an estimated $10.8K.
  • ProShare Advisors first reported a position in aTyr Pharma in Q4 2015 and held it in 8 quarters.
  • ProShare Advisors's aTyr Pharma position peaked at $196K in Q4 2015.
  • 89 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.